Using two potent tyrosine-kinase and VEGFR inhibitor, one of them approved for clinical use to treat specific tumors such as renal cell carcinoma, gastro-intestinal stromal tumors or pancreatic neuroendocrine tumors22, we further demonstrate that VEGFR inhibition impairs extravasation of circulating tumor cells by blocking the endothelial remodeling. Here, KDR is linked to hereditary clear cell renal cell carcinoma.